No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.
No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.
复制标题
没有证据表明接受雷迪帕韦-索磷布韦治疗丙型肝炎病毒感染的患者中乙型肝炎病毒重新激活。
DOI：
10.1093/cid/ciw507
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Gane,Edward
中科院分区：
文献类型：
--
作者：
Sulkowski,MarkS;Chuang,Wan-Long;Kao,Jia-Horng;Yang,JennyC;Gao,Bing;Brainard,DianaM;Han,Kwang-Hyub;Gane,Edward
已报告丙型肝炎治疗期间B型肝炎病毒（HBV）再激活的上市后病例。我们分析了在台湾和韩国进行的ledipasvir-sofosbuvir临床试验中患者的血清样本。在入选的173例患者中，103例（60%）既往感染过HBV。无一例显示HBV再激活的证据。
Postmarketing cases of hepatitis B virus (HBV) reactivation during hepatitis C treatment have been reported. We analyzed serum samples from patients in a clinical trial of ledipasvir-sofosbuvir in Taiwan and Korea. Of the 173 patients enrolled, 103 (60%) had been previously infected with HBV. None showed evidence of HBV reactivation.